Ligand Pharmaceuticals Incorporated Stock News

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received full approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. Ligand is entitled to milestone paym...

Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Global CD40 Ligand Market by Type (Monoclonal Antibody, Polyclonal Antibody), Application (Autoimmune Disease Treatment, Immunotherapy, Vaccine Development), End-Users - Forecast 2024-2030" report has been added to ResearchAndMarkets.com's offering. The CD40 Ligand Market size was estimated at USD 697.21 million in 2023, USD 734.50 million in 2024,...

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on Tuesday, September 10, 2024, at 8:30 a.m. Eastern Time. Management is scheduled to host one-on-one meetings with investors a...

The top five biotech stocks today have several commonalities. Among them are strong ratings.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Todd Davis - CEO Tavo Espinoza - CFO Paul Hadden - Senior Vice President of Investments and Business Development Karen Reeves - Senior Vice President of Investments and Head of Clinical Strategy Conference Call Participants Matt Hewitt - Craig-Hallum Douglas Miehm -...

Ligand Pharmaceuticals has seen over a 50% increase in share value since its Q1 earnings report. Recent positive developments include new deals, regulatory successes, and raising 2024 guidance. A new deal of close to $200 million with Agenus and $100 million acquisition of APEIRON contribute to the positive outlook.

Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies Combined company is expected to have approximately $80.5 million of cash and cash equivalents at closing, including approximately $78.9 million from an oversubscribed p...

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and Webcas...